Altimmune (ALT) Non-Current Assets (2010 - 2026)
Altimmune (ALT) reported Non-Current Assets of $954000.0 for Q1 2026, down 52.32% year-over-year from $2.0 million in Q1 2025, and down 45.08% on a QoQ basis from $1.7 million in Q4 2025.
Altimmune (ALT) has 17 years of Non-Current Assets data on file, last reported at $954000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 52.32% year-over-year to $954000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 22.45% YoY) and the FY2025 annual result came in at $1.7 million, down 15.35% from the prior year.
- Non-Current Assets slipped to $954000.0 in Q1 2026 per ALT's latest filing, from $1.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $14.6 million in Q1 2022 and bottomed at $843000.0 in Q1 2024.
- The 5-year median for Non-Current Assets is $2.1 million (2024), against an average of $6.8 million.
- The widest annual swing landed in 2024, when Non-Current Assets sank 93.97%; it then soared 137.37% in 2025.
- Tracing ALT's Non-Current Assets over 5 years: stood at $14.1 million in 2022, then sank by 92.82% to $1.0 million in 2023, then soared by 102.37% to $2.1 million in 2024, then fell by 15.35% to $1.7 million in 2025, then plunged by 45.08% to $954000.0 in 2026.
- Per Business Quant, the three latest ALT Non-Current Assets figures stand at $954000.0 (Q1 2026), $1.7 million (Q4 2025), and $1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 954,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 954,000.00 |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 843,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 13.61 Mn |
| Jun 30, 2023 | 13.78 Mn |
| Mar 31, 2023 | 13.97 Mn |
| Dec 31, 2022 | 14.12 Mn |
| Sep 30, 2022 | 14.27 Mn |
| Jun 30, 2022 | 14.40 Mn |
| Mar 31, 2022 | 14.57 Mn |
| Dec 31, 2021 | 14.74 Mn |
| Sep 30, 2021 | 18.64 Mn |
| Jun 30, 2021 | 18.64 Mn |
| Mar 31, 2021 | 19.06 Mn |
| Dec 31, 2020 | 14.86 Mn |
| Sep 30, 2020 | 14.86 Mn |
| Jun 30, 2020 | 14.57 Mn |
| Mar 31, 2020 | 14.60 Mn |
| Dec 31, 2019 | 14.66 Mn |
| Sep 30, 2019 | 14.76 Mn |
| Jun 30, 2019 | 15.87 Mn |
| Mar 31, 2019 | 15.96 Mn |
| Dec 31, 2018 | 15.38 Mn |
| Sep 30, 2018 | 40.90 Mn |
| Jun 30, 2018 | 40.24 Mn |
| Mar 31, 2018 | 40.95 Mn |
| Dec 31, 2017 | 39.56 Mn |
| Sep 30, 2017 | 48.22 Mn |
| Jun 30, 2017 | 73.85 Mn |
| Mar 31, 2017 | 2.44 Mn |
| Dec 31, 2016 | 33.91 Mn |
| Sep 30, 2016 | 2.50 Mn |
| Jun 30, 2016 | 2.53 Mn |
| Mar 31, 2016 | 2.60 Mn |
| Dec 31, 2015 | 2.64 Mn |
| Sep 30, 2015 | 2.65 Mn |
| Jun 30, 2015 | 2.71 Mn |
| Mar 31, 2015 | 2.73 Mn |
| Dec 31, 2014 | 2.73 Mn |
| Jun 30, 2014 | 2.79 Mn |
| Mar 31, 2014 | 2.79 Mn |
| Dec 31, 2013 | 2.80 Mn |
| Sep 30, 2013 | 2.85 Mn |
| Jun 30, 2013 | 2.89 Mn |
| Mar 31, 2013 | 2.90 Mn |
| Dec 31, 2012 | 2.95 Mn |
| Sep 30, 2012 | 3.03 Mn |
| Jun 30, 2012 | 3.12 Mn |
| Mar 31, 2012 | 3.22 Mn |
| Dec 31, 2011 | 3.19 Mn |
| Sep 30, 2011 | 3.30 Mn |
| Jun 30, 2011 | 3.38 Mn |
| Dec 31, 2010 | 3.62 Mn |